

## **AGENDA**

### **The Impact of Genomic Profiling on Patients with Prostate Cancer**

April 29, 2021

5 PM ET



**LUGPA**  
Integrated Practices  
Comprehensive Care

Introduction:

**Neal Shore, MD**

3 minutes

#### **Session 1:**

Risk Stratification of Newly Diagnosed Prostate Cancer

**Ted Schaffer, MD**

10 minutes

Germline and Somatic Mutations

**Emmanuel Antonarakis, MD**

10 minutes

#### **Session 2**

Biomarkers Outside of Germline and Somatic Mutations

**Misha Beltran, MD**

10 minutes

Integrating Genetic Testing into Clinical Practice for Advanced Prostate Cancer

**Heather Cheng, MD**

10 minutes

Conclusion

**Neal Shore, MD and Dave Morris, MD**

4 minutes -

#### **Description:**

The role and importance of genetic testing for both high risk newly diagnosed prostate cancer patients as well as those with advanced cancer will be discussed, and how it will affect personalized care decisions in addition to family member education for testing and cancer screening. Urologist need to be aware and equipped to understand and use genetic profiling to optimize the patient treatment plan. This course is designed to close the gap in practice by improving awareness, knowledge and competence of genomic profiling to optimize patients with newly diagnosed prostate cancer.

#### **Desired outcome:**

As a result of this activity urologists will understand and be more aware of the use genetic testing and profiling to uncover conditions that are undetected using other tests - to better manage patient care and strategies to incorporate genetic testing/profiling into their practice.

#### **Learning objectives:**

At the conclusion of this activity participants will be able to:

Review the differences in genetic testing for prostate cancer patients: germline vs somatic

Explain when, how, who and why testing should be performed.

Create a pathway for patient counseling and develop a pathway for optimal testing.

Review the importance of family history assessment for all urology patients who may have a hereditary risk for cancer.

**References:**

Malone, E.R., Oliva, M., Sabatini, P.J.B. *et al.* Molecular profiling for precision cancer therapies. *Genome Med* **12**, 8 (2020). <https://doi.org/10.1186/s13073-019-0703-1>